Click on headlines below to download research

Diversified strategy showing its strength
Oxford BioMedica | 09/11/2018

Strong operational momentum at Oxford BioMedica (OXB), as evidenced by its interim maiden operating profit of £9.4m (vs a loss of £2.2m in…

Golden age for LentiVector as Axovant signs deal
Oxford BioMedica | 08/06/2018

Oxford BioMedica (OXB) has signed an out-licensing deal with Axovant for its Parkinson’s disease (PD) gene therapy AXO-Lenti-PD (previously OXB-102)…

Validation achieved, growth expected
Oxford BioMedica | 10/05/2018

Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica (OXB) has become one of a handful…